Consun Pharmaceutical Group Limited

Informe acción SEHK:1681

Capitalización de mercado: HK$5.3b

Consun Pharmaceutical Group Dirección

Dirección controles de criterios 3/4

El CEO de Consun Pharmaceutical Group's es Meng An , nombrado en Jan 2024, tiene una permanencia de menos de un año. compensación anual total es CN¥16.76M, compuesta por 6.6% salario y 93.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.83% de las acciones de la empresa, por valor de HK$80.94M. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 3.4 años, respectivamente.

Información clave

Meng An

Chief Executive Officer (CEO)

CN¥19.8m

Compensación total

Porcentaje del salario del CEO5.5%
Permanencia del CEOless than a year
Participación del CEO1.8%
Permanencia media de la dirección3.6yrs
Promedio de permanencia en la Junta Directiva3.6yrs

Actualizaciones recientes de la dirección

Recent updates

Consun Pharmaceutical Group's (HKG:1681) Dividend Will Be CN¥0.30

May 12
Consun Pharmaceutical Group's (HKG:1681) Dividend Will Be CN¥0.30

Consun Pharmaceutical Group (HKG:1681) Is Increasing Its Dividend To CN¥0.30

Jun 01
Consun Pharmaceutical Group (HKG:1681) Is Increasing Its Dividend To CN¥0.30

Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

May 04
Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

Consun Pharmaceutical Group (HKG:1681) Will Pay A Dividend Of HK$0.20

Apr 28
Consun Pharmaceutical Group (HKG:1681) Will Pay A Dividend Of HK$0.20

Consun Pharmaceutical Group (HKG:1681) Has Announced A Dividend Of HK$0.20

Apr 07
Consun Pharmaceutical Group (HKG:1681) Has Announced A Dividend Of HK$0.20

Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10

Aug 26
Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly

Apr 21
Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly

Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?

Mar 17
Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?

Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative

Feb 19
Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative

How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 29
How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?

Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?

Jan 08
Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly

Dec 18
Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly

Should Consun Pharmaceutical Group Limited (HKG:1681) Be Part Of Your Income Portfolio?

Nov 18
Should Consun Pharmaceutical Group Limited (HKG:1681) Be Part Of Your Income Portfolio?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Meng An en comparación con los beneficios de Consun Pharmaceutical Group?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2023CN¥20mCN¥1m

CN¥785m

Sep 30 2023n/an/a

CN¥759m

Jun 30 2023n/an/a

CN¥734m

Mar 31 2023n/an/a

CN¥708m

Dec 31 2022CN¥17mCN¥1m

CN¥683m

Sep 30 2022n/an/a

CN¥660m

Jun 30 2022n/an/a

CN¥636m

Mar 31 2022n/an/a

CN¥613m

Dec 31 2021CN¥14mCN¥670k

CN¥590m

Compensación vs. Mercado: La compensación total de Meng($USD2.31M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD394.47K).

Compensación vs. Ingresos: La compensación de Meng ha sido consistente con los resultados de la empresa en el último año.


CEO

Meng An (53 yo)

less than a year

Permanencia

CN¥19,793,000

Compensación

Mr. Meng An serves as Executive Chairman of the Board at Consun Pharmaceutical Group Limited since July 9, 2021 and serves a sits Chief Executive Officer from January 17, 2024. Mr. An being the Chairman of...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Meng An
CEO & Executive Chairmanless than a yearCN¥19.79m1.76%
CN¥ 93.7m
Quan Zhu
Chief Scientist & Executive Director3.6yrsCN¥742.00ksin datos
Hanxing Xu
Assistant GM3.3yrsCN¥774.00ksin datos
Peicheng Fang
CFO & VP4.3yrssin datossin datos
Lei Zhou
Assistant President4.4yrssin datossin datos
Haien Gao
Board Secretary10.2yrssin datossin datos
Chi Ming Yau
Company Secretary11.3yrssin datossin datos
Guorong Guo
Chairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd3.6yrssin datossin datos
Lianhui Chen
Chairman & GM of Consun Pharmaceutical(Inner Mongolia) Co. Ltd3.6yrssin datossin datos

3.6yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1681 se considera experimentado (3.4 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Meng An
CEO & Executive Chairman3.3yrsCN¥19.79m1.76%
CN¥ 93.7m
Quan Zhu
Chief Scientist & Executive Director11.5yrsCN¥742.00ksin datos
Hanxing Xu
Assistant GM3.3yrsCN¥774.00ksin datos
Guorong Guo
Chairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd3.6yrssin datossin datos
Lianhui Chen
Chairman & GM of Consun Pharmaceutical(Inner Mongolia) Co. Ltd3.6yrssin datossin datos
Zhongshi Feng
Independent Non-Executive Director10.5yrsCN¥200.00ksin datos
Yujun Chen
Independent Non Executive Director5.1yrsCN¥200.00ksin datos
Lihua Zhang
Non-Executive Director2.9yrssin datossin datos

3.6yrs

Permanencia media

49.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 1681 se considera experimentada (3.4 años de antigüedad promedio).